Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2021-09-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于为子公司提供担保的进展公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the progress of guarantees provided by the parent company to its subsidiaries. It details the approval of guarantee limits, specific guarantee contracts signed, guarantee scope, duration, and cumulative guarantee amounts. There is no financial statement, audit report, or detailed financial analysis present. The document is relatively short (1370 characters) and serves as a regulatory disclosure about guarantees, which is typical for regulatory filings. It does not fit into categories like Annual Report, Interim Report, or Capital Update. It is not a report publication announcement since it contains substantive information rather than just announcing a report's release. Therefore, the best classification is Regulatory Filings (RNS).
2021-09-16 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, compliance with regulations, and other procedural information. It does not contain financial statements or earnings data but focuses on the company's buyback activity. The document length is short (1383 characters) and is clearly an update on share repurchase progress, fitting the definition of a Transaction in Own Shares (POS) filing.
2021-09-01 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 90% confidence The document is a special statement and independent opinion by independent directors regarding the company's related party transactions, specifically about the use of company funds by controlling shareholders and external guarantees. It references compliance with laws and regulations and provides a detailed explanation of the situation during the reporting period ending June 30, 2021. This type of document is a standalone audit-related statement focusing on internal controls and compliance, not a full annual report or financial statement. It is not a brief announcement or a certification letter but a formal audit-related opinion. Therefore, it fits best under Audit Report / Information (AR). The document length is short but contains substantive content related to audit and compliance. H1 2021
2021-08-25 Chinese
半年报董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from 葵花药业集团股份有限公司 regarding the approval of the 2021 half-year report (interim report). It states that the 2021 half-year report and its summary have been disclosed on official information platforms. The document itself is the announcement of the board meeting decision approving the interim report, not the interim report itself. The document length is short (755 characters), and it mainly announces the approval and disclosure of the interim report rather than containing substantive financial data or analysis. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of the board resolution and report disclosure, not the interim report itself (IR).
2021-08-25 Chinese
2021年半年度财务报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the 2021 semi-annual financial report of 葵花药业集团股份有限公司, containing detailed financial statements such as consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity. The presence of comprehensive financial data for a half-year period, including income, expenses, assets, liabilities, and equity, indicates this is a substantive interim financial report. The document length is about 15,000 characters, which is consistent with a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-25 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021年半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also includes management discussion on business performance and strategic initiatives during the reporting period. The length is about 4050 characters, which is sufficient to contain substantive financial data and analysis. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. It is not merely an announcement or a summary without data, nor is it a full annual report or other filing type. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2021
2021-08-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.